Shilpa Medicare. has filed a patent for pharmaceutical compositions in the form of a suspension for oral delivery. The composition includes active ingredients like quetiapine, sildenafil, and others. The patent claims have been canceled. GlobalData’s report on Shilpa Medicare gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Shilpa Medicare, Nanoparticle drug conjugates was a key innovation area identified from patents. Shilpa Medicare's grant share as of January 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
The filed patent (Publication Number: US20230372238A1) includes claims related to a pharmaceutical oral suspension and an immunosuppressive method. The patent describes a pharmaceutical oral suspension containing mycophenolate mofetil at a concentration of about 200 mg/mL, xanthan gum at about 2 mg/mL, glycerin at about 100 mg/mL, and various other pharmaceutically acceptable excipients such as antifoaming agents, buffers, flavoring agents, preservatives, sweeteners, and wetting agents. The suspension is formulated in a vehicle comprising water.
Furthermore, the patent outlines an immunosuppressive method that involves administering a therapeutically effective amount of the pharmaceutical oral suspension to a patient in need of immunosuppressive treatment. This method aims to provide a convenient and effective way to deliver mycophenolate mofetil, an immunosuppressive agent, to patients requiring such treatment. By formulating the drug in an oral suspension with specific concentrations of key ingredients and excipients, the patent seeks to optimize the therapeutic benefits of mycophenolate mofetil while ensuring patient compliance and ease of administration.
To know more about GlobalData’s detailed insights on Shilpa Medicare, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
